Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| AURA | EFFECT | bearish | 4/10 | Aura Biosciences' S-3 shelf registration (File No. 333-298228) became effective on August 20, 2026, allowing the company | Aug 21, 2026 |
| CUE | EFFECT | bearish | 6/10 | Cue Biopharma's S-3 shelf registration (File No. 333-298266) became effective on August 20, 2026, enabling the company t | Aug 21, 2026 |
| ALLO | EFFECT | bearish | 4/10 | Allogene Therapeutics' S-3 shelf registration (File No. 333-298268) became effective on August 20, 2026. This allows the | Aug 21, 2026 |
| CXXIF | 6-K | bearish | 5/10 | C21 Investments filed Q1 FY2027 results showing a significant operational deterioration: revenue fell 10.8% YoY to $7.6M | Aug 21, 2026 |
| ATHE | 6-K | neutral | 2/10 | Alterity Therapeutics filed a Form 6-K with an exhibit (Exhibit 99.1) titled 'Application for quotation of securities - | Aug 21, 2026 |
| BAK | 6-K | bearish | 8/10 | Braskem responded to a B3 inquiry regarding an O Globo report that it is preparing to file for an out-of-court reorganiz | Aug 21, 2026 |
| CRVS | INST-CLUSTER | bullish | 6/10 | A strong institutional cluster formed in CRVS during 2026-Q2, with 15 buyers accumulating $24.8M in holdings (net +$14.6 | Aug 21, 2026 |
| CAPR | INST-CLUSTER | mixed | 5/10 | During 2026-Q2, 18 institutional buyers accumulated $29.1M in CAPR while 6 sellers reduced holdings by $53.1M, for net s | Aug 21, 2026 |
| TVRD | INST-CLUSTER | bearish | 4/10 | In Q2 2026, 9 institutional sellers reduced TVRD holdings by ~$1.85M, led by BlackRock (near-exit, -$1.05M), Geode (trim | Aug 21, 2026 |
| CMPX | INST-CLUSTER | bullish | 7/10 | A strong institutional cluster in CMPX shows 15 buyers adding $37.2M in positions (net +$9.2M) vs 5 sellers reducing by | Aug 21, 2026 |
| AMPH | INST-CLUSTER | mixed | 4/10 | Institutional cluster for AMPH shows mixed conviction in Q2 2026: 12 buyers accumulated $13.1M in new positions, led by | Aug 21, 2026 |
| KROS | CLUSTER | neutral | 4/10 | Keros Therapeutics insiders executed a mixed cluster: one director bought $10K worth of shares, while three C-suite offi | Aug 21, 2026 |
| TWST | CLUSTER | neutral | 3/10 | Three Twist Bioscience insiders, CEO Emily Leproust, President/COO Patrick Finn, and Director Katryn Blake, sold a combi | Aug 21, 2026 |
| RCKT | CLUSTER | neutral | 4/10 | Four Rocket Pharmaceuticals insiders, including CEO Gaurav Shah and COO Christopher Stevens, sold a total of $164K in op | Aug 21, 2026 |
| ARWR | CLUSTER | neutral | 2/10 | Two directors at Arrowhead Pharmaceuticals sold a combined $1.19M in open-market sales on August 18, 2026. This is a sma | Aug 21, 2026 |
| CRL | CLUSTER | neutral | 3/10 | Three CRL insiders, including CEO Birgit Girshick, sold a total of ~$3.0M in shares over a 7-day window. The CEO's $1.82 | Aug 21, 2026 |
| CORT | CLUSTER | neutral | 4/10 | A cluster of insider selling at Corcept Therapeutics, led by Director David Mahoney ($12.2M) and CBO Gary Robb ($1.16M), | Aug 21, 2026 |
| NTHI | CLUSTER | bullish | 6/10 | Two top executives at NEONC TECHNOLOGIES (CEO Thomas Chen and President/CEO Amir Heshmatpour) made open-market purchases | Aug 20, 2026 |
| AZN | COURT-RULING | neutral | 2/10 | A federal magistrate judge granted AstraZeneca's request to limit the temporal scope of a corporate deposition in a pend | Aug 20, 2026 |
| MANE | 3 | neutral | 2/10 | David Hollander filed a Form 3 initial statement of beneficial ownership with the SEC, disclosing his role as Chief R&D | Aug 20, 2026 |
| COLL | COURT-RULING | mixed | 5/10 | Collegium Pharmaceutical won partial dismissal of Walgreens' breach-of-contract lawsuit in Massachusetts federal court. | Aug 20, 2026 |
| RNA | PRESS-RELEASE | neutral | 2/10 | Atrium Therapeutics granted inducement stock options and RSUs totaling 11,000 shares and 5,500 shares, respectively, to | Aug 20, 2026 |
| ADPT | CLUSTER | neutral | 4/10 | ADPT CEO Chad Robins and two directors sold a total of $8.19M in open-market stock over two days, with the CEO alone sel | Aug 20, 2026 |
| QNRX | 8-K | neutral | 2/10 | Quoin Pharmaceuticals filed an 8-K reporting results from its 2026 Annual General Meeting. Shareholders approved routine | Aug 20, 2026 |
| NMRA | 144 | bearish | 5/10 | Director Daljit Singh Aurora filed a Form 144 notice to sell 134,452 shares (~$203,584) via a broker-assisted cashless e | Aug 20, 2026 |
| SNTI | 8-K | bearish | 6/10 | Senti Biosciences issued an additional $4.0M in Senior Secured Convertible Notes to Celadon Partners under a previously | Aug 20, 2026 |
| INBP | 8-K | neutral | 2/10 | Integrated BioPharma's wholly-owned subsidiary Manhattan Drug Company appointed Michael Richtmyer as Head of Operations, | Aug 20, 2026 |
| HCWB | S-1 | neutral | 5/10 | HCW Biologics filed an S-1 registration statement to register the resale of up to 1,237,364 shares of common stock by se | Aug 20, 2026 |
| PTIX | 8-K | bullish | 6/10 | Protagenic Therapeutics received written FDA pre-IND feedback for its lead candidate PT00114 in generalized anxiety diso | Aug 20, 2026 |
| MRK | ANALYST-UPGRADE | mixed | 5/10 | Morgan Stanley upgraded Merck & Co., Inc. (MRK) from Equal-Weight to Overweight on August 20, 2026, with a new price tar | Aug 20, 2026 |